The historical rank and industry rank for Pacira BioSciences's ROE % or its related term are showing as below:
FRA:82P'
s ROE % Range Over the Past 10 Years
Min: -17.35 Med: 0.4 Max: 29.86
Current: 0.71
During the past 13 years, Pacira BioSciences's highest ROE % was 29.86%. The lowest was -17.35%. And the median was 0.40%.
FRA:82P's ROE % is ranked worse than 66.45% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs FRA:82P: 0.71
Pacira BioSciences (FRA:82P) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Pacira BioSciences ROE % Related Terms
Pacira BioSciences ROE % Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's ROE % distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Pacira BioSciences (FRA:82P) has a ROE % of 1.74% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pacira BioSciences and its competitors. This is 335% above median its historical median of 0.40. According to the industry distribution chart, Pacira BioSciences ranks #622 out of 936 companies in the Drug Manufacturers industry, placing it in the top 66.5%.
Is Pacira BioSciences' ROE % too high?
Pacira BioSciences' current ROE % of 1.74% is 335% above median its 10-year median of 0.40. The Drug Manufacturers industry median ROE % is 5.87. Pacira BioSciences' value of 1.74% is 70.3% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #622 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' ROE % compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #622 out of 936 companies for ROE %. This places Pacira BioSciences in the lower half of its industry. The industry median ROE % is 5.87. Pacira BioSciences' value of 1.74% is 70.3% below this benchmark. While the company's 10-year median is 0.40 vs. the industry median of 5.87, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current ROE % of 1.74% is 70.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current ROE % is 1.74%, which is 335% above median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current ROE % of 1.74%. The stock's GF Value™ is €25.35, compared to a current price of €20.60 — trading 18.7% below its estimated fair value. The current ROE % is 1.74%, which is 335% above median its 10-year median of 0.40 and 70.3% below the Drug Manufacturers industry median of 5.87. Pacira BioSciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current ROE % is 1.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €20.60 is trading 18.7% below its estimated GF Value™ of €25.35.
Key valuation signals for FRA:82P:
ROE %: 1.74% (335% above median its 10-year median of 0.40)
GF Value™: €25.35 vs. price of €20.60 (18.7% below fair value)
Industry Position: 70.3% below the Drug Manufacturers median (#622 of 936)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
74GF Score
Get the complete analysis for FRA:82P
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
